Phanes Therapeutics Begins Clinical Examining of Peluntamig for Cancer Therapy

Phanes Therapeutics Initiates First Patient Dosing for Peluntamig (PT217) in Combination with Chemotherapy

Phanes Therapeutics, Inc., a clinical-stage biotech firm specializing in innovative drug discovery and oncology development, has made a significant stride in cancer treatment by announcing the dosing of the first patient in its clinical trial for peluntamig (PT217). This innovative therapy is being evaluated alongside traditional chemotherapy regimens, seeking to address critical medical needs in patients with small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC), including neuroendocrine prostate cancer (NEPC).

Peluntamig (PT217) is notable for being a first-in-class native IgG-like bispecific antibody that simultaneously targets DLL3 and CD47. This unique mechanism of action holds promise for improving treatment outcomes in specific cancer types. The U.S. Food and Drug Administration (FDA) has recognized its potential, granting it orphan drug designations for both SCLC and NEC, as well as Fast Track status for extensive-stage SCLC that progresses following chemotherapy treatments.

The clinical trial is part of a multi-center Phase I/II study, known as the SKYBRIDGE study, designed to explore peluntamig's safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced cancers that express DLL3. Additionally, there is an ongoing Phase I study of peluntamig (PT217) in China, demonstrating the international commitment to exploring this promising treatment.

Phanes Therapeutics' collaboration with Roche highlights the synergetic effort to enhance treatment strategies in oncology, as they investigate peluntamig in combination with Roche's anti-PD-L1 therapy, atezolizumab. This partnership further enriches the clinical landscape, providing patients with innovative therapeutic options.

About Phanes Therapeutics

Phanes Therapeutics is dedicated to developing cutting-edge therapies in the oncology field. The company has initiated three Phase I/II clinical trials, including the MORNINGSTAR study for mavrostobart (PT199), and the TWINPEAK study centered on spevatamig (PT886). Both of these candidates, alongside peluntamig, are significant as first-in-class bispecific antibodies that have also received orphan drug and Fast Track designations from the FDA.

Using proprietary technology platforms such as PACbody®, SPECpair®, and ATACCbody®, Phanes Therapeutics is focused on creating innovative biologic treatments that can meet the high unmet medical needs within the oncology landscape. The company's commitment to advancing cancer therapies is evident as it leverages these technologies to propel its pipeline forward.

With the global burden of cancer continuing to rise, initiatives like the ongoing trials for peluntamig mark crucial steps in developing effective treatments that can significantly impact patient outcomes. As the study unfolds, the oncology community eagerly anticipates the results, hoping for breakthroughs that could reshape treatment standards.

For further information about Phanes Therapeutics and its clinical programs, visit www.phanesthera.com. Inquiries regarding media or business development can be directed to their respective contact emails provided on their website.